Compare SOBR & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SOBR | JAGX |
|---|---|---|
| Founded | 2004 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Newspapers/Magazines | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4M | 2.2M |
| IPO Year | 2008 | 2014 |
| Metric | SOBR | JAGX |
|---|---|---|
| Price | $0.75 | $1.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $60.00 |
| AVG Volume (30 Days) | ★ 13.8M | 56.3K |
| Earning Date | 04-10-2026 | 04-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 103.55 | 82.42 |
| EPS | ★ N/A | N/A |
| Revenue | $437,421.00 | ★ $11,511,000.00 |
| Revenue This Year | N/A | $61.58 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 105.62 | N/A |
| 52 Week Low | $0.35 | $0.22 |
| 52 Week High | $4.50 | $8.00 |
| Indicator | SOBR | JAGX |
|---|---|---|
| Relative Strength Index (RSI) | 46.76 | 24.67 |
| Support Level | $0.57 | $0.96 |
| Resistance Level | $0.94 | $1.98 |
| Average True Range (ATR) | 0.31 | 0.24 |
| MACD | 0.05 | -0.15 |
| Stochastic Oscillator | 17.80 | 13.00 |
Sobr Safe Inc is a hardware and software company. The Company integrates proprietary software, SOBRsafeTM, with its patented touch-based personal alcohol awareness tracking products, SOBRcheckTM and SOBRsure, enabling non-invasive personal alcohol awareness tracking, biometric identity verification, and qualified, real-time cloud-based, informational alerts and reporting. It operates as a single segment designed to enable customers to purchase products directly through channel partners, sales agents or through its enterprise and consumer digital channels. Currently its principal markets are located in North America.
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.